Cell Therapy Associated With Endobronchial Valve

NCT04018729 | Recruiting Phase 2 FDA Device

• 1 other identifier: 2018-0327
• Study Type: interventional
• Target: 34
• Locations: 1 country
• Sites: 1

Brief Summary

Chronic obstructive pulmonary disease (COPD) is one of the most common diseases worldwide and is considered a public health problem. The World Health Organization estimates that about 210 million people have COPD. Disease-related mortality is more than 3 million, representing 5% of all deaths, 90% of this mortality being concentrated in middle- and low-income countries. COPD can be subdivided into chronic bronchitis and emphysema. Emphysema, the focus of this project, is histologically defined by the permanent increase of the distal air spaces to the terminal bronchioles associated with the destruction of the alveolar septa in the lung. Approximately two-thirds of adult men and a quarter of women (most without dysfunction) will have well-defined emphysema, but often of limited extent. Mesenchymal stem cells (MSCs) have anti-inflammatory, anti-fibrotic, microbicide and repair potential. Regarding COPD, several authors have concentrated efforts in the investigation of the relationship between the severity of the condition and the various sources of adult stem cells. Apparently the lungs have a high chemotactic effect in relation to adult stem cells, since several studies have evidenced a high implantation (6-20%) of stem cells derived from bone marrow, administered systemically, in the pulmonary tissue of receptors. Therefore, MSCs has been tested in different lung diseases have no effective treatment, such as pulmonary fibrosis, acute respiratory distress syndrome, asthma, COPD positive results, such as reduction of fibrosis, reduction of proliferation inflammatory cells and cytokines, reduction of infectious processes and recovery of the histological changes caused by pulmonary emphysema. Based on these findings, the purpose of this project is to evaluate the safety and efficacy of endoscopic administration of bone marrow stem cells in patients with severe homogeneous emphysema and evaluating the feasibility, efficacy and safety of this procedure.

Conditions

Chronic Obstructive Pulmonary Disease Severe

Outcome Measures

Primary Outcomes (5)

• All-cause death

  Expressed as the total number of death due to all conditions during the clinical trial.

  6 months

• Number of participants with worsening of dyspnea

  Number of participants with worsening of dyspnea as measured by the mMRC-Modified Medical Research Council (1 point increase in the measured scale). The mMRC Dyspnea Scale quantifies disability attributable to breathlessness (range from 1-4), and is useful for characterizing baseline dyspnea in patients with respiratory diseases.

  6 months

• Number of participants with respiratory functional worsening

  Number of participants with respiratory functional worsening as measured by decrease of 15% or more in FEV1 (forced expiratory volume in one second). FEV1 is a measurement taken from a pulmonary function test. It calculates the amount of air that a person can force out of their lungs in 1 second.

  6 months

• Impairment of exercise capacity

  Impairment of exercise capacity as measured by reduction of 35 m in the 6-minute walk test. The 6-min walk test (6 MWT) is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The test provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.

  6 months

• Increased oxygen use

  Outcome measure result: number of participants with 1 point increase in oxygen need as classification on the chart above 0 - no oxygen use 1- intermittent use \<6h/day 2- intermittent use \>6h/dia 3 - continuous oxygen use

  6 months

Study Arms (2)

Endobronchial valve + marrow-derived mesenchymal stromal cell

EXPERIMENTAL

Device: Zephyr Endobronchial Valve; Biological: Marrow-derived mesenchymal stromal cell

Endobronchial valve

ACTIVE COMPARATOR

Device: Zephyr Endobronchial Valve

Interventions

Zephyr Endobronchial Valve DEVICE

Endoscopic lung volume reduction therapy.

Endobronchial valve; Endobronchial valve + marrow-derived mesenchymal stromal cell

Marrow-derived mesenchymal stromal cell BIOLOGICAL

Mesenchymal stem cells have anti-inflammatory, anti-fibrotic, microbicide and repair potential.

Endobronchial valve + marrow-derived mesenchymal stromal cell

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of severe heterogeneous pulmonary emphysema (at least 10% of total lung parenchyma or 25% of target lobe with density \< -950HU);
• Heterogeneity\> 15pp (difference of at least 15 percentage points of lung parenchyma with density greater than -950HU between the treated lobe(s) and the remaining lung on the same side)
• Estimates of low or non-existent collateral ventilation (fissure integrity\> 95% measured by VIDA Diagnostics or collateral ventilation measured by negative Chartis® System)
• Total lung capacity\> 100% of predicted
• Residual volume\> 175% of predicted
• FEV1 \<50% of predicted post-bronchodilator
• DLCO (diffusing capacity of the lungs for carbon monoxide) \<45% of predicted post-bronchodilator
• Body Mass Index (BMI) Greater than 18Kg/m2 and less than 35Kg/m2.
• Optimized clinical treatment
• Daily physical activities limitation
• Possibility of pulmonary rehabilitation
• Preserved ventricular function (LVEF\> 40%)
• Cessation of smoking ≥ 4 months
• Dyspnea MMRC ≥ 2

You may not qualify if:

• Homogeneous emphysema
• Estimated collateral ventilation observed on CT scanned by VIDA vision software (VIDA vision®, VIDA Diagnostics, Iowa-USA) - Fissure integrity on target lobe less than 75%.
• Use of continuous systemic corticosteroid therapy\> 20mg QD (quaque die, once a day) of prednisone (or equivalent)
• Active lung or extra pulmonary infection
• Coronary heart disease and/or severe ventricular dysfunction
• Significant renal or hepatic disease
• Immunosuppressive disease
• Rheumatologic or orthopedic disease limiting physical capacity;
• Cognitive inability to understand study procedures;
• Impression by clinical research investigators with a lifespan of less than a year1;
• Active smoking
• Malignant neoplasia with estimated prognosis of survival \<2 years
• Psychosocial problems
• Pregnancy

Sponsors & Collaborators

• Hospital de Clinicas de Porto Alegre: lead
• Pontifícia Universidade Católica do Paraná: collaborator
• Universidade Federal do Rio de Janeiro: collaborator

Study Sites (1)

Hospital de Clinicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, 90035903, Brazil

RECRUITING

Study Officials

• Hugo G Oliveira, PhD

  Hospital de Clinicas de Porto Alegre

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Hugo G Oliveira, PhD

CONTACT

+55 51 3359-8241; hugo@hugooliveira.org

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 10, 2019
• First Posted: July 12, 2019
• Study Start: November 19, 2019
• Primary Completion: August 17, 2020
• Study Completion (Estimated): April 30, 2029
• Last Updated: December 14, 2022

Record last verified: 2022-12

Data Sharing

• IPD Sharing: Will not share

Locations

BR (1)